The chemical class known as PSMB4 inhibitors encompasses a diverse group of compounds specifically designed to selectively target and modulate the activity of PSMB4 (Proteasome Subunit Beta 4). PSMB4 is a critical subunit of the proteasome, a large multi-protein complex responsible for degrading intracellular proteins. The proteasome plays a crucial role in regulating various cellular processes, including protein turnover, cell cycle progression, and antigen presentation. PSMB4 inhibitors aim to disrupt the function of the proteasome by specifically targeting the PSMB4 subunit. By inhibiting PSMB4, these compounds potentially interfere with the degradation of specific proteins, leading to the accumulation of unwanted or damaged proteins within the cell. This disruption may have implications for various cellular pathways and functions.
The chemical structures of PSMB4 inhibitors can vary widely, including small molecules, peptides, and other compounds designed to specifically interact with PSMB4 or its associated subunits. Additionally, certain inhibitors may exert broader effects on the proteasome due to the interconnection of its subunits in the complex. Researchers use PSMB4 inhibitors as valuable tools in understanding proteasome function, protein regulation, and cellular processes. By selectively targeting PSMB4, these inhibitors enable investigations into the specific roles of this subunit within the proteasome complex and its contribution to cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib (brand name Velcade) is a well-known proteasome inhibitor studied in the research of certain types of cancer. It targets multiple subunits of the proteasome, including PSMB4, leading to the accumulation of unwanted proteins and triggering cell death. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib (brand name Kyprolis) is another proteasome inhibitor investigated for multiple myeloma. It targets PSMB5 more specifically but can also inhibit other proteasome subunits, including PSMB4. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX-0914 is a selective inhibitor of the immunoproteasome, a specialized form of the proteasome that is involved in antigen presentation. It targets PSMB8, a subunit of the immunoproteasome that is structurally related to PSMB4. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is another investigational proteasome inhibitor that can inhibit PSMB4 along with other proteasome subunits. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that has shown inhibitory effects on PSMB4 in research studies. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
MLN9708 is the citrate form of Ixazomib, and it is also a proteasome inhibitor that can target PSMB4. | ||||||